Mid-sized pharma companies having brands that are not in top-ten in their therapies are likely to face the most brunt if doctors are compel...

"A presentation was made to the PMO in this regard and the concern of the Laghu Udyog Bharati was also discussed. A decision is likely to b...

The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers has sought tweaking of paragraph 19 of the DPCO for the f...

The confusion over which diseases are to be considered as “rare” and which drugs as “orphan” (used to treat rare diseases) has led to the d...

The government plans to fix TMR in a phased manner and has identified 139 formulations which include drugs like Remdesivir, Tocilizumab, in...

The representatives of Organisation of Pharmaceutical Producers of India (OPPI), which represents multinational pharma companies and domest...

Bridge Policy Think Tank, a legal research foundation which undertakes legislative and policy research, has been asked to do a comparative ...

Representatives of several small and medium pharma companies have suggested that the government adopt a "one molecule-one MRP" formula inst...

The meeting was attended by representatives from the Indian Drug Manufacturers Association (IDMA) and Indian Pharmaceutical Alliance (IPA),...

"The total annual savings on account of revision of ceiling prices of medicines under the National List of Essential Medicines (NLEM), pric...

The Department of Pharmaceuticals along with the Drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA) will discuss the ...

In a meeting held earlier this month with Niti Aayog, DoP also suggested that trade margin on all formulations and dosages be capped at 100...

HCG has filed a writ petition with the Karnataka High Court challenging the decision of the National Pharmaceutical Pricing Control.

As per data available with NPPA, the MRP for 105 brands will be reduced up to 85 per cent entailing minimum saving of Rs 105 crore to consu...

Unlike price caps, fixing trade margins would restrict how much a product’s price can be raised from the import or manufacturing cost.

At present, BCD on formulations is 10% (other than specified drugs, life saving drugs, vaccines and bulk drugs for which the BCD rate is 5%...

Wholesale and retail dealers in pharma today staged a protest here against the J & K govt's new drug policy, claiming that it would severel...